Implications of Biomarker Discordance After Coronary Artery Revascularization: The EXCEL Trial

Björn Redfors; John Gregson; Ori Ben-Yehuda; Patrick W. Serruys; Arie Pieter Kappetein; Joseph F. Sabik; Stuart J. Pocock; Gregg W. Stone

doi:10.1016/j.jacc.2021.04.033

Implications of Biomarker Discordance After Coronary Artery Revascularization: The EXCEL Trial

Björn Redfors, John Gregson, Ori Ben-Yehuda, Patrick W. Serruys, Arie Pieter Kappetein, Joseph F. Sabik, Stuart J. Pocock, Gregg W. Stone

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	2978-2980
Number of pages	3
Journal	Journal of the American College of Cardiology
Volume	77
Issue number	23
DOIs	https://doi.org/10.1016/j.jacc.2021.04.033
State	Published - 15 Jun 2021

Access to Document

10.1016/j.jacc.2021.04.033

Cite this

@article{c5ea86ad49f34a11a178cf0c133bff68,

title = "Implications of Biomarker Discordance After Coronary Artery Revascularization: The EXCEL Trial",

author = "Bj{\"o}rn Redfors and John Gregson and Ori Ben-Yehuda and Serruys, {Patrick W.} and Kappetein, {Arie Pieter} and Sabik, {Joseph F.} and Pocock, {Stuart J.} and Stone, {Gregg W.}",

note = "Funding Information: The EXCEL trial was funded by Abbott Vascular. Dr. Serruys is a consultant for Sinomed, SMT, Philips/Volcano, Xeltis, Novartis, and Meril Life. Dr. Kappetein is an employee of Medtronic. Dr. Sabik is a consultant for Medtronic; and is an advisory board member for Medtronic Cardiac Surgery. Dr. Stone is a speaker or has received other honoraria from Cook, Terumo, QOOL Therapeutics, and Orchestra Biomed; is a consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, Matrizyme, and Cardiomech; and has equity/options from Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, BioStar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, MedFocus family of funds, and Valfix. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: The EXCEL trial was funded by Abbott Vascular. Dr. Serruys is a consultant for Sinomed, SMT, Philips/Volcano, Xeltis, Novartis, and Meril Life. Dr. Kappetein is an employee of Medtronic. Dr. Sabik is a consultant for Medtronic; and is an advisory board member for Medtronic Cardiac Surgery. Dr. Stone is a speaker or has received other honoraria from Cook, Terumo, QOOL Therapeutics, and Orchestra Biomed; is a consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, Matrizyme, and Cardiomech; and has equity/options from Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, BioStar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, MedFocus family of funds, and Valfix. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.",

year = "2021",

month = jun,

day = "15",

doi = "10.1016/j.jacc.2021.04.033",

language = "English",

volume = "77",

pages = "2978--2980",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier Inc.",

number = "23",

}

TY - JOUR

T1 - Implications of Biomarker Discordance After Coronary Artery Revascularization

T2 - The EXCEL Trial

AU - Redfors, Björn

AU - Gregson, John

AU - Ben-Yehuda, Ori

AU - Serruys, Patrick W.

AU - Kappetein, Arie Pieter

AU - Sabik, Joseph F.

AU - Pocock, Stuart J.

AU - Stone, Gregg W.

N1 - Funding Information: The EXCEL trial was funded by Abbott Vascular. Dr. Serruys is a consultant for Sinomed, SMT, Philips/Volcano, Xeltis, Novartis, and Meril Life. Dr. Kappetein is an employee of Medtronic. Dr. Sabik is a consultant for Medtronic; and is an advisory board member for Medtronic Cardiac Surgery. Dr. Stone is a speaker or has received other honoraria from Cook, Terumo, QOOL Therapeutics, and Orchestra Biomed; is a consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, Matrizyme, and Cardiomech; and has equity/options from Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, BioStar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, MedFocus family of funds, and Valfix. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: The EXCEL trial was funded by Abbott Vascular. Dr. Serruys is a consultant for Sinomed, SMT, Philips/Volcano, Xeltis, Novartis, and Meril Life. Dr. Kappetein is an employee of Medtronic. Dr. Sabik is a consultant for Medtronic; and is an advisory board member for Medtronic Cardiac Surgery. Dr. Stone is a speaker or has received other honoraria from Cook, Terumo, QOOL Therapeutics, and Orchestra Biomed; is a consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, Matrizyme, and Cardiomech; and has equity/options from Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, BioStar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, MedFocus family of funds, and Valfix. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2021/6/15

Y1 - 2021/6/15

UR - http://www.scopus.com/inward/record.url?scp=85107140774&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2021.04.033

DO - 10.1016/j.jacc.2021.04.033

M3 - Letter

C2 - 34112324

AN - SCOPUS:85107140774

SN - 0735-1097

VL - 77

SP - 2978

EP - 2980

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 23

ER -